INS and metabolic syndrome: The reduction in the prevalence of patients meeting the criteria for metabolic syndrome was significantly greater with pooled tirzepatide doses compared to placebo, semaglutide 1 mg, insulin glargine, and insulin degludec (p < 0.001, all comparisons).